M. Nasiri, Marjan Farzad, Majid Zare Bidaki, Hanieh Hakhamaneshi, T. Kazemi, A. Kooshki
{"title":"COVID-19疫苗接种后心肌炎的叙述性回顾","authors":"M. Nasiri, Marjan Farzad, Majid Zare Bidaki, Hanieh Hakhamaneshi, T. Kazemi, A. Kooshki","doi":"10.26502/fccm.92920254","DOIUrl":null,"url":null,"abstract":"Citation Kooshki. A Narrative Review of Myocarditis Following COVID-19 Vaccination. Cardiology and Cardiovascular Medicine 6 (2022): 189-195. Abstract M yocarditis is a rare but serious consequence of COVID-19 vaccination. This study conducted a narrative review of the research on vaccine-induced myocarditis regarding the type, dose of vaccine, time to present from the vaccine, cardiac history, the patients were males. The age range was 14-70 years with a mean age of 28.82±14.65 years. The majority of the myocarditis related COVID-19 vaccine cases (73.9%) were associated with the Pfizer-BioNTech following the second dose of the vaccine. The median time to present from the vaccines was 3 days (range, 1-14 days). 93.5% of cases had no previous cardiac history. 91.3% of myocarditis cases were survived and discharged from the hospital.","PeriodicalId":72523,"journal":{"name":"Cardiology and cardiovascular medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Narrative Review of Myocarditis Following COVID-19 Vaccination\",\"authors\":\"M. Nasiri, Marjan Farzad, Majid Zare Bidaki, Hanieh Hakhamaneshi, T. Kazemi, A. Kooshki\",\"doi\":\"10.26502/fccm.92920254\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Citation Kooshki. A Narrative Review of Myocarditis Following COVID-19 Vaccination. Cardiology and Cardiovascular Medicine 6 (2022): 189-195. Abstract M yocarditis is a rare but serious consequence of COVID-19 vaccination. This study conducted a narrative review of the research on vaccine-induced myocarditis regarding the type, dose of vaccine, time to present from the vaccine, cardiac history, the patients were males. The age range was 14-70 years with a mean age of 28.82±14.65 years. The majority of the myocarditis related COVID-19 vaccine cases (73.9%) were associated with the Pfizer-BioNTech following the second dose of the vaccine. The median time to present from the vaccines was 3 days (range, 1-14 days). 93.5% of cases had no previous cardiac history. 91.3% of myocarditis cases were survived and discharged from the hospital.\",\"PeriodicalId\":72523,\"journal\":{\"name\":\"Cardiology and cardiovascular medicine\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiology and cardiovascular medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26502/fccm.92920254\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology and cardiovascular medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/fccm.92920254","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A Narrative Review of Myocarditis Following COVID-19 Vaccination
Citation Kooshki. A Narrative Review of Myocarditis Following COVID-19 Vaccination. Cardiology and Cardiovascular Medicine 6 (2022): 189-195. Abstract M yocarditis is a rare but serious consequence of COVID-19 vaccination. This study conducted a narrative review of the research on vaccine-induced myocarditis regarding the type, dose of vaccine, time to present from the vaccine, cardiac history, the patients were males. The age range was 14-70 years with a mean age of 28.82±14.65 years. The majority of the myocarditis related COVID-19 vaccine cases (73.9%) were associated with the Pfizer-BioNTech following the second dose of the vaccine. The median time to present from the vaccines was 3 days (range, 1-14 days). 93.5% of cases had no previous cardiac history. 91.3% of myocarditis cases were survived and discharged from the hospital.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
